Sector News

UCB acquires gene therapy specialist Handl Therapeutics

November 13, 2020
Life sciences

Company also announces new collaboration with Lacerta Therapeutics.

UCB has announced its acquisition of Belgium-based gene therapy company Handl Therapeutics, in a move that will bolster its pipeline programmes, capabilities and platforms in the gene therapy space.

UCB also announced a new collaboration with Lacerta Therapeutics, a clinical stage gene therapy company based in Florida, US.

Handl Therapeutics is focused on creating disease modifying in vivo gene therapies to treat neurodegenerative disease through proprietary adeno-associated virus (AAV) capsid technology.

According to UCB, Handl has a strong international network which enables access to global capabilities and expertise – the company combines technology platforms and scientific advances licenced from KU Leuven (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navarra, Spain), University of Chile (Chile) and King’s College London (UK).

Following the acquisition by UCB, the Handl Therapeutics team will continue to be based in Leuven, Belgium while working closely with UCB’s international research teams.

In addition to its acquisition of Handl Therapeutics, UCB has also signed a research collaboration and licensing agreement with Lacerta Therapeutics.

The focus of this agreement is to make AAV-based therapies for central nervous system (CNS) diseases with high unmet need.

Lacerta is set to lead the research, preclinical activities and early manufacturing process development, while UCB will lead IND-enabling studies, manufacturing and clinical development.

“The acquisition of Handl Therapeutics and the new partnership with Lacerta Therapeutics offers us the potential to drive a fundamental change in how diseases are treated, by moving us from treating symptoms to disease modification and eventually towards a cure,” said Dhavalkumar Patel, chief scientific officer of UCB.

“We are delighted to be able to welcome a rich diversity of talent and expertise from both Handl Therapeutics and Lacerta Therapeutics. With their deep and wide-ranging knowledge, novel gene therapy platforms and drive for innovation, I am confident that together we will transform the lives of people living with severe neurodegenerative diseases,” he added.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).